Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-3427?

AZD-3427 is commercialized by AstraZeneca, with a leading Phase II program in Pulmonary Hypertension.

Related Posts

ANeuroTech shares plans for major depressive disorder p...

Jun 17, 2023

US FDA approves Bausch + Lomb and Novaliq’s DED treatm...

May 20, 2023

STAT+: FTC countersues HCA, Louisiana hospital system t...

Apr 21, 2023